UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.          )
Filed by the Registrant ☒	
Filed by a Party other than the Registrant  ☐	
Check the appropriate box:	
 ☐	Preliminary Proxy Statement	
 ☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))	
☐	Definitive Proxy Statement	
 ☒	Definitive Additional Materials	
 ☐	Soliciting Material under §240.14a-12	

Bristol-Myers Squibb Company	
(Name of Registrant as Specified In Its Charter)	
   	
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	

Payment of Filing Fee (Check the appropriate box):	
☒	No fee required.	
 ☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.	
 	(1)	Title of each class of securities to which transaction applies:	
 	 	 	
 	(2)	Aggregate number of securities to which transaction applies:	
 	 	 	
 	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
 	 	 	
 	(4)	Proposed maximum aggregate value of transaction:	
 	 	 	
 	(5)	Total fee paid:	
 	 	 	
 ☐	Fee paid previously with preliminary materials.	
 ☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.	
 	(1)	Amount Previously Paid:	
 	 	 	
 	(2)	Form, Schedule or Registration Statement No.:	
 	 	 	
 	(3)	Filing Party:	
 	 	 	
 	(4)	Date Filed:	

 Proxy Season Update  April 2021 

 To discover, develop and deliver innovative medicines that help patients prevail over serious diseases  2  Our mission 

 2020 A Year of Strong Performance   Continued to strengthen our diversified portfolio with leading positions in Oncology, Hematology, Immunology and CardiovascularA 63% increase in total revenues, or 7%* on a pro forma basisStrengthened the company with important business development transactions, including the acquisition of MyoKardia, Inc., expanding our cardiovascular portfolioSignificant pipeline progress with several key regulatory milestones:received approval of new medicines, including Zeposia for multiple sclerosis, Reblozyl for myelodysplastic syndromes, and Onureg for acute myeloid leukemiasubmitted regulatory filings for CAR-T therapies, Breyanzi (liso-cel) for relapsed or refractory large B-cell lymphoma and Abecma (ide-cel) for 4L+ relapsed refractory multiple myeloma** achieved eight positive clinical trial readouts, including:Positive top line results from Phase 3 True North trial evaluating Zeposia in patients with moderate to severe ulcerative colitis Phase 3 trial evaluating deucravacitinib (BMS-986165), a novel oral selective tyrosine kinase 2 (TYK2) inhibitor for treatment of patients with moderate to severe plaque psoriasisMultiple Opdivo positive studies (CM-9ER, CM-649, CM-577, CM-816, CM-274)  3  **Liso-cel and ide-cel approved in first quarter of 2021    2020 Full Year Revenues  $42.5B  GAAP Full Year  *Assumes acquisition of Celgene and divestiture of Otezla® to Amgen Inc. occurred on January 1, 2019 and excludes foreign currency hedge gains and losses. See “Worldwide Pro Forma Revenue” in Quarterly Package of Financial Information for full year of 2020, which is available on bms.com/investors/financial-reporting/quarterly-results. 

 Company Response to COVID-19  4  Expanded patient support programs to help eligible unemployed patients in the USExpanded access to free BMS medicines, including some of our most widely prescribed products and those prescribed via telehealth servicesMaintained uninterrupted supply of medicines to patientsIn 2020, the company made over $11 million in COVID-19 related cash donations and grants to organizations in 38 countriesThe Bristol Myers Squibb Foundation donated over $21 million in aid in 42 countries  People  Patients  Business  Health & Safety remains top priorityMajority of workforce remains remote; staged return subject to guidance from local health authoritiesEssential workers provided with testing, protective equipment and flexibility to address individual needs, with strong focus on well-beingBMS donated over $1 million in personal protective equipment (PPE) to organizations in the USWe empower our people with an inclusive and energizing work environment tailored to our values and focusing on well-being and resiliency  COVID-19 Prevention & Treatment:We entered into a global licensing agreement with Rockefeller University to potentially develop an antibody combo for therapy or prevention of COVID- 19Working with several cross-industry groups & partnerships (e.g., Bill & Melinda Gates Foundation) to accelerate the development, manufacturing, and delivery of diagnostics and treatments for COVID-19We have identified more than 1,000 proprietary compounds to be made available to collaborators with high-quality assays, to screen for possible molecules to treat COVID-19Development & Supply of our Medicines:No critical supply chain impacts; all sites distribution networks remain operationalClinical Trials:Clinical trial recruitment showing sustained recoveryProof-of-concept clinical trial in progress to assess the safety and efficacy of Orencia (abatacept) in hospitalized patients 

 Our Commitment to Sustainability & Diversity and Inclusion  Our approach to sustainability is global and encompasses the products we make, how we make them, access to our medicines, our facilities, our people and our communitiesWe conduct our business in ways that contribute to economic opportunity, social responsibility, and a healthy environment, today and tomorrowThis is reflected in our sustainability goals, which put measurable goals against these areas of focus  Accelerate innovation and develop transformative medicinesEnhance patient access to medicines  Patients  5  Empower our people with an energizing work environment and safety culture  People  Drive supply chain leadership on quality and integrityInnovate to support a green, healthy planet  Business    Diversity and Inclusion  Supplier Diversity  Employee Giving  Workforce Representation  Clinical Trial Diversity  Reach underserved communities in urban and rural U.S. geographies; train and develop 250 new investigators   Identify and activate under-utilized sites in the most racially and ethnically diverse metro areas in the United States  Health Disparities  Accelerate disease awareness and education programs with at-risk patients; advocate for policies that promote health equity  Award $50 million in U.S. health equity grants in BMS therapeutic areas by the end of 2021  Spend $1 billion globally by 2025 with Black/African American and other diverse-owned businesses  Provide a 2-to-1 match through the Bristol Myers Squibb Foundation for U.S. and Puerto Rico employee donations to organizations that fight disparities and discrimination  Achieve gender parity at the executive level globally and double representation from June 2020 levels of both Black/African American executives (3.0% to 6.0%) and Hispanic/Latino executives (3.7% to 7.4%) in the U.S. by year-end 2022  Sustainability 

 Environmental Progress Made in 2020*  6  20.7%Reduction inGHG emissions  Reduced energyconsumed13.3%  10.8%Less water used  Increased EV/hybrid in fleet19.2%  Reduce wastegenerated59.1%  300%Increase in recycled/reclaimed efforts  *Figures shown in infographic are 2019 metrics against 2015 baseline.(does not include former Celgene sites). 

 Committed to Sound Corporate Governance  7  Board Accountability and Shareholder Rights  Regular shareholder engagementAnnual election of DirectorsMajority voting standard for election of DirectorsRobust Lead Independent Director roleLimit on public company board memberships for BMS Directors (4)Limit on total board memberships for sitting CEO (2)  Proxy access shareholder rightAbility to call special meetings (25%)*Extensive related party transaction policies and proceduresNo supermajority voting provisions for common stockholdersNo stockholder rights planSemi-annual political contributions disclosures  *Current management proposal to decrease the special meeting threshold to 15% 

 Giovanni Caforio, M.D. More than 19 years of experience at Bristol-Myers Squibb, including previous role as COO  Board Well Equipped to Support Company Strategies  8  Karen Vousden, Ph.D. Chief Scientist at Cancer Research UK Senior Group Leader at the Francis Crick Institute in LondonFormer Director, Beatson Institute for Cancer Research UKPresident of the British Association of Cancer Research Committees: S&T (c); CMDC  Gerald L. StorchFormer CEO of Hudson’s Bay Company.Former CEO and Chairman of Toys “R” Us, Inc.Former Vice Chairman of Target Corp. Committees: CMDC (c), CDCG  Audit: Audit Committee CDCG: Committee on Directors & Corporate GovernanceCMDC: Compensation & Management Development Committee S&T: Science & Technology Committee C: Committee chair  * = New Since 2020  Theodore R. SamuelsRetired President of Capital Guardian Trust CompanyCommittees: CDCG (c), Audit  Phyllis YaleAdvisory partner with Bain & Co., Chair of the Board of Blue Cross Blue Shield of MassachusettsFormer Board member of Kindred Healthcare, National Surgical Hospitals, Value Options, Pediatric Services of American and NeighborCare Committees: Audit, CDCG  Julia A. Haller. M.D.Ophthalmologist-in-Chief of Wills Eye Hospital Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College Committees: CDCG, S&T  Peter J. ArduiniPresident and Chief Executive Officer, Integra LifeSciences Holdings CorporationCommittees: CMDC, S&T  Michael W. BonneyChair of the Board of Kaleido Biosciences and former CEO and ChairmanFormer CEO of Cubist PharmaceuticalsFormer VP, Sales & Marketing at BiogenCommittees: Audit, S&T  Derica Rice*Former Executive Vice President of CVS Health and President, Pharmacy Benefits Business of CVS Caremark Former Executive Vice President of Global Services and CFO of Eli Lilly and CompanyCommittees: Audit (c), CMDC  Paula Price*Former Executive Vice President and CFO of Macy's, Inc.Former Executive Vice President and CFO of Ahold USAFormer Chief Accounting Officer of CVS CaremarkCommittees: Audit, CDCG  5-10 years(3 Directors)  Tenure  Diversity 

 90% performance-based   Executive Compensation Supporting our Strategy    Continued Commitment to our Compensation Philosophy and Structure  Pay for PerformanceA substantial proportion of our executives’ pay is variable, at-risk based on our financial and operational results and delivered in the form of equity, supporting alignment over the long term between our executives and our shareholders  Competitive Pay ProgramAttracts, retains, and incentivizes talented executives capable of leading our business in a highly complex and competitive environment  1  2    Sound Compensation Governance Practices  100% performance-based annual and long-term incentivesCaps on payouts under annual and long-term incentive award programsRobust share ownership and share retention guidelinesNeutralize share buyback impact on share-denominated compensation metricsRobust recoupment and clawback policiesRegular shareholder engagement“Double-trigger” change-in-control agreementsNo guaranteed incentive with our Named Executive OfficersProhibition on speculative and hedging transactionsProhibition on pledging shares and holding them in a margin accountProactively eliminate windfall gain potentialNo employment contracts with our Named Executive OfficersProhibition on re-pricing or backdating of equity awardsMinimal perquisites to our Named Executive Officers  Performance Share Units 46%   2020 CEO CompensationCEO target compensation between the median & 75th percentile of our peer group90% of target pay is performance based75% of target pay deliveredin long term equity incentives with multi-year vesting    2020 Target Total CEO Compensation  9 

   2020 Compensation Plan  10  *Items outlined with dotted line are updates to the 2020 Compensation Program  Base Salary  Annual Incentive (Paid in cash)  Allows us to attract and retain talent in a highly competitive labor marketBased on specialized qualifications, experience and role impact, and pay levels of comparable positions within peer groupSalary increases based on competitive market, individual performance and size of company wide annual budget  Company Performance Factors      Individual Performance Factor  EPS(30%)  Critical measure of annual profitability, aligning our employees with our shareholders    Committee judgment applied against pre-defined and measureable operational, financial, and strategic objectivesClear performance objectives are set at the beginning of each year to align with our company’s goalsExecutives are assessed on “Results” and demonstration of “Values” – assessments are used as the basis for making individual compensation decisions  Revenues(25%)  Foundation of long-term sustainable growth and competitive superiority      Pipeline(25%)  Near-Term Value   Have evolved to:Drive improved decision-making and operational rigor Ensure alignment with combined company’s portfolio      Long-Term Growth Potential        Qualitative Overlay      Key Integration Metrics(20%)  Human Capital Management(50%)  Retain and develop critical talent to support our strategy and deliver on merger priorities      Synergies(50%)  Reflects commitment to deliver merger deal synergies.    Important component of attracting specialized talentRewards creation of incremental shareholder valueProvides a mix of short, medium and long-term performance periodsMulti-year vesting helps to promote retention while maintaining pay-for-performance link  Long-Term Incentive (Paid in shares)  Performance Share Units (60%)  Market Share Units (40%)  Rewards the achievement of financial goals and further aligns executive compensation with the interests of our shareholders — Operating Margin (33%), Total Revenues (33%) and relative Total Shareholder Return (34%), each measured over an applicable three year performance period.        

 We Value Your Support at Our 2021 Annual Meeting  11   FOR Election of Directors FOR Advisory Vote to Approve the Compensation of our Named Executive Officers FOR Approval of the Company’s 2021 Stock Award and Incentive Plan FOR Approval of the Appointment of an Independent Registered Public Accounting Firm FOR Approval of an Amendment to Company’s Amended and Restated Certificate of Incorporation to Lower the Ownership Threshold for Special Shareholder Meetings to 15%    AGAINST Adoption of a Board Policy that the Chairperson of the Board be an Independent Director AGAINST Shareholder Right to Act by Written Consent AGAINST Lowering the Ownership Threshold for Special Shareholder Meetings to 10%  2021 Bristol Myers Squibb Board Recommendations  Management Proposals  Shareholder Proposals 

 We Value Your Support at Our 2021 Annual Meeting (continued)  12  Management Proposal on the Approval ofCompany’s 2021 Stock Award and Incentive Plan  The 2021 Plan is an “omnibus” plan, authorizing a variety of equity award types as well as cash incentive awards. The 2021 Plan is similar in scope to our existing 2012 Stock Award and Incentive Plan. We intend that the 2021 Plan will replace the 2012 Plan, under which the authorization to grant awards is set to expire in 2022. Our Board and Compensation and Management Development Committee seek shareholder approval of the 2021 Plan so that awards under the Plan can help us:Attract, retain and motivate officers, employees, directors, and other service providers to Bristol Myers Squibb and its subsidiaries and affiliates,Provide competitive compensation opportunities, Reward achievement of our business goals, and Promote creation of long-term value for shareholders by closely aligning the interests of Plan participants with the interests of shareholders.The Board and the Committee believe that awards linked to common stock and awards with terms tied to our performance provide incentives for the achievement of important performance objectives and promote the long-term success of Bristol-Myers Squibb. Therefore, the 2021 Plan is expected to be an integral part of our overall compensation program.   Accordingly, our Board recommends a vote FOR these management proposals  Management Proposal on Approval of an Amendment to Company’s Amended and Restated Certificate of Incorporation to Lower the Ownership Threshold for Special Shareholder Meetings to 15%  We are committed to high standards of corporate governance, including taking steps to achieve greater transparency and accountability to our shareholders. As such, at this Annual Meeting, the Board is asking shareholders to approve an amendment to the Company’s Certificate of Incorporation to reduce the percentage of outstanding shares required for shareholders to call a special meeting from 25% to 15%. The Board has determined to take this action following extensive engagement with our shareholders and an evaluation of our strong corporate governance policies and practices, including the many ways shareholders are able to contact the Board and senior management on important matters outside of the annual meeting cycle. The Board believes that a 15% threshold strikes an appropriate balance between enhancing shareholder access and minimizing the potential harms associated with allowing a small number of shareholders with special interests to call special shareholder meetings.The Proposed Charter Amendment is binding. If this proposal is approved by the holders of a majority of the outstanding shares of the company, a Certificate of Amendment to our Certificate of Incorporation to implement the Proposed Charter Amendment will be filed with the Secretary of State of the State of Delaware.  

 We Value Your Support at Our 2021 Annual Meeting (continued)  13  Shareholder Proposal on the Adoption of a Board policy that the Chairperson of the Board be an Independent Director  After careful consideration, the Board did not feel that this proposal deserved its support. The Board believes different board structures are appropriate for different companies at different times. At our 2017 annual meeting, our CEO, Dr. Giovanni Caforio, was elected to become Chairman of the Board. The Board took numerous factors into account in approving this structure. These included:The Board believes that shareholder interests are well served when the Board has the flexibility to determine the most appropriate leadership structure based on an assessment of the Company’s needs and circumstances at any given time,The Board believes our Company and its shareholders benefit from this flexibility, as our directors are well positioned to determine our leadership structure given their in-depth knowledge of our leadership team, our strategic goals, and the opportunities and challenges we face, the strong roles played by our Lead Independent Director and the independent chairs of each of our key board committees, the independence-protecting features of our corporate governance guidelines, andHaving one individual serve in both roles positions Dr. Caforio to effectively drive future strategy and decision-making for the Company and ensures that the Company presents its message and strategy to all stakeholders with a unified voice. The Board believes having a Chairman who not only has extensive industry experience but also deep institutional knowledge of the Company serve as the Chief Executive Officer is highly advantageous for the Company at this time.Over the last two decades the Board has had different leadership structures depending on the needs of the Board and the company at the time. In particular, from 2005 until 2007 and from 2010 until 2017, the Board had a separated Chairman and CEO.  Accordingly, our Board recommends a vote AGAINST these shareholder proposals  Shareholder Proposal on Shareholder Right to Act by Written Consent   After careful consideration, the Board did not feel that this proposal deserved its support. The request to give shareholders the right to act by written consent is unnecessary given our company’s strong corporate governance profile, including the ability of shareholders to call special meetings.Action by written consent would enable the holders of just a majority of our outstanding shares to take action on a proposal without the benefits of hearing the views, questions and arguments of other shareholders or the company.Action by written consent eliminates the need for advance notice to be given to shareholders about a proposed action, and therefore, certain shareholders may not be informed about the proposed action until after the action has already been taken. The company is committed to high standards of corporate governance and has already taken a number of steps to achieve greater transparency and accountability to shareholders, including through the adoption of proxy access shareholder right.The written consent process that this proposal seeks to authorize can be cumbersome, time consuming, costly and may lead to unnecessary disruption to the company. The Board believes that holding meetings where all shareholders may discuss the proposed actions and vote their shares is the best way for shareholders to take action and helps to ensure the accuracy and completeness of information presented to shareholders to obtain their approval.  

 We Value Your Support at Our 2021 Annual Meeting (continued)  14  The company is committed to high standards of corporate governance, including taking steps to achieve greater transparency and accountability to our shareholders. As such, at this Annual Meeting, the Board is asking shareholders to approve an amendment to the Company’s Certificate of Incorporation to reduce the percentage of outstanding shares required for shareholders to call a special meeting from 25% to 15%. The Board has determined to take this action following extensive engagement with our shareholders and an evaluation of our strong corporate governance policies and practices, including the many ways shareholders are able to contact the Board and senior management on important matters outside of the annual meeting cycle. Convening a special shareholder meeting is costly and time consuming. The Company believes that its proposed 15% threshold strikes the appropriate balance between giving shareholders the ability to call special meetings and protecting the Company’s resources.Our strong corporate governance policies and practices, including the ability of a reasonable minority of shareholders to call special meetings, already provide our shareholders with the ability to raise important matters with the Board and senior management.  Shareholder Proposal on Shareholder to Lower the Ownership Threshold for Special Shareholder Meetings to 10%  Accordingly, our Board recommends a vote AGAINST this shareholder proposal and FOR the management proposal to lower the ownership threshold for special shareholder meetings to 15% 

 Forward-Looking Information and Non-GAAP Financial Information  This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the Company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available on the SEC’s website, on the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations.In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.This presentation includes certain non-generally accepted accounting principals (GAAP) financial measures that we use to describe our company’s performance. The non-GAAP information presented provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly –filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measure are available on our website at bms.com/investors.  15